Food , drug , insect sting allergy , and anaphylaxis Hypersensitivity reactions to mAbs : 105 desensitizations in 23 patients , from evaluation to treatment

[1]  H. Albrecht,et al.  Fundamentals of antibody-related therapy and diagnostics. , 2009, Drugs of today.

[2]  M. Castells,et al.  Acetylsalicylic acid and montelukast block mast cell mediator-related symptoms during rapid desensitization. , 2009, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[3]  M. Jerath,et al.  A desensitization protocol for the mAb cetuximab. , 2009, The Journal of allergy and clinical immunology.

[4]  U. Matulonis,et al.  Food , drug , insect sting allergy , and anaphylaxis Hypersensitivity reactions to chemotherapy : Outcomes and safety of rapid desensitization in 413 cases , 2022 .

[5]  S. Misbah,et al.  Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. , 2008, The New England journal of medicine.

[6]  Quynh-Thu Le,et al.  Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. , 2008, The New England journal of medicine.

[7]  G. Vena,et al.  Hypersensitivity reactions to last generation chimeric, humanized [correction of umanized] and human recombinant monoclonal antibodies for therapeutic use. , 2008, Current pharmaceutical design.

[8]  A. Litonjua,et al.  Prevalence and titer of IgE antibodies to mouse allergens. , 2007, The Journal of allergy and clinical immunology.

[9]  J. Berlin,et al.  High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  K. Price,et al.  Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. , 2007, Allergy and asthma proceedings.

[11]  B. Dijkmans,et al.  Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis , 2007, Annals of the rheumatic diseases.

[12]  A. Lefvert,et al.  The clinical significance of HAMA in patients treated with mouse monoclonal antibodies , 1992, Cell Biophysics.

[13]  M. Castells.  Desensitization for drug allergy , 2006, Current opinion in allergy and clinical immunology.

[14]  B. Wallaert,et al.  Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions , 2006, Alimentary pharmacology & therapeutics.

[15]  M. Castells.  Mast cell mediators in allergic inflammation and mastocytosis. , 2006, Immunology and allergy clinics of North America.

[16]  D. Dreyfus,et al.  Characterization of an anaphylactoid reaction to omalizumab. , 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[17]  Ludwig Kappos,et al.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[18]  U. Matulonis,et al.  Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. , 2005, Gynecologic oncology.

[19]  M. Castells,et al.  Antigen-IgE desensitization in signal transducer and activator of transcription 6-deficient mast cells by suboptimal doses of antigen. , 2005, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[20]  A. Tonnel,et al.  Accoutumance médicamenteuse à l'infliximab dans la maladie de Crohn , 2005 .

[21]  U. Matulonis,et al.  Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. , 2005, Gynecologic oncology.

[22]  C. Rand,et al.  Airborne mouse allergen in the homes of inner-city children with asthma. , 2005, The Journal of allergy and clinical immunology.

[23]  B. Wallaert,et al.  [Desensitisation to infliximab in patients with Crohn's disease]. , 2005, Revue des maladies respiratoires.

[24]  D. MacGlashan,et al.  Loss of syk kinase during IgE-mediated stimulation of human basophils. , 2004, The Journal of allergy and clinical immunology.

[25]  S. Brown.  Clinical features and severity grading of anaphylaxis. , 2004, The Journal of allergy and clinical immunology.

[26]  C. Rand,et al.  Environmental and occupational respiratory disorders Mouse allergen exposure and mouse skin test sensitivity in suburban, middle-class children with asthma , 2004 .

[27]  R. Dillman.  Infusion Reactions Associated with the Therapeutic Use of Monoclonal Antibodies in the Treatment of Malignancy , 2004, Cancer and Metastasis Reviews.

[28]  E. Haddad,et al.  Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti–interleukin-2 receptor monoclonal antibody basiliximab , 2003, Transplantation.

[29]  D. McGill,et al.  Severe hypotension complicating primary angioplasty: allergy to abciximab , 2003, Allergy.

[30]  K. Meeran,et al.  Interfering antibodies affecting immunoassays in woman with pet rabbits , 2003, BMJ : British Medical Journal.

[31]  An Carbonez,et al.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.

[32]  K. Woodside,et al.  Safe administration of a humanized murine antibody after anaphylaxis to a chimeric murine antibody , 2002, Transplantation.

[33]  Jon E. Stahlman,et al.  Rapid desensitization and rush immunotherapy to trastuzumab (Herceptin). , 2002, The Journal of allergy and clinical immunology.

[34]  R. Aster,et al.  Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. , 2002, Blood.

[35]  D. Palisaitis,et al.  Potential Anaphylactic Shock with Abciximab Readministration , 2002, Pharmacotherapy.

[36]  N. Cook-Bruns.  Retrospective Analysis of the Safety of Herceptin® Immunotherapy in Metastatic Breast Cancer , 2001, Oncology.

[37]  L. Rybicki,et al.  Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  S. Kugathasan,et al.  Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction. , 2001, Inflammatory bowel diseases.

[39]  A. Özden,et al.  Severe anaphylactic reaction to infliximab: report of a case , 2000, American Journal of Gastroenterology.

[40]  P. Lipsky,et al.  Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial , 1999, The Lancet.

[41]  C. White,et al.  Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. , 1999, Seminars in oncology.

[42]  A. Santoro,et al.  Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine. , 1999, Seminars in oncology.

[43]  J. Byrd,et al.  Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  R. Bush,et al.  Laboratory animal allergy. , 1998, The Journal of allergy and clinical immunology.

[45]  F. Levi-Schaffer,et al.  Responsiveness of human skin mast cells to repeated activation: an in vitro study , 1998, Allergy.

[46]  B. Klein,et al.  Human anti‐mouse antibody response to the injection of murine monoclonal antibodies against IL‐6 , 1994, Clinical and experimental immunology.

[47]  J. Kinet,et al.  Phosphorylation/dephosphorylation of high-affinity IgE receptors: a mechanism for coupling/uncoupling a large signaling complex. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[48]  J. Georgitis,et al.  Anaphylaxis and desensitization to the murine monoclonal antibody used for renal graft rejection. , 1991, Annals of allergy.

[49]  R. Patterson,et al.  Desensitization of human basophils with suboptimal concentrations of agonist. Evidence for reversible and irreversible desensitization. , 1988, Immunology.

[50]  L. Chatenoud,et al.  Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. , 1986, Journal of immunology.

[51]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[52]  P. Gell,et al.  Clinical aspects of immunology , 1968 .

[53]  P. Ehrlich,et al.  Croonian lecture.—On immunity with special reference to cell life , 1900, Proceedings of the Royal Society of London.